The objective of this review is to explore the available literature on solid renal masses (SRMs) in transplant allograft kidneys to better understand the epidemiology and management of these tumors. A literature review using PubMed was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology. Fifty-six relevant studies were identified from 1988 to 2015. A total of 174 SRMs in 163 patients were identified, with a mean tumor size of 2.75 cm (range 0.5-9.0 cm). Tumor histology was available for 164 (94.3%) tumors: clear cell renal cell carcinoma (RCC; 45.7%), papillary RCC (42.1%), chromophobe RCC (3%), and others (9.1%). Tumors were managed by partial nephrectomy (67.5%), radical nephrectomy (19.4%), percutaneous radiofrequency ablation (10.4%), and percutaneous cryoablation (2.4%). Of the 131 patients (80.3%) who underwent nephronsparing interventions, 10 (7.6%) returned to dialysis and eight (6.1%) developed tumor recurrence over a mean follow-up of 2.85 years. Of the 110 patients (67.5%) who underwent partial nephrectomy, 3.6% developed a local recurrence during a mean followup of 3.12 years. The current management of SRMs in allograft kidneys mirrors management in the nontransplant population, with notable findings including an increased rate of papillary RCC and similar recurrence rates after partial nephrectomy in the transplant population despite complex surgical anatomy.
Introduction
Renal transplantation has emerged as the gold standard treatment for end-stage renal disease (ESRD). Among patients who have undergone renal transplantation, the long-term mortality rate is 48-82% lower than those remaining on the transplant waitlist (1) . These patients, however, are at a twofold increased risk of developing a malignancy compared with the general healthy population (2) . The incidence of renal cell carcinoma (RCC) in allograft kidneys is low (0.19-0.5%) (3, 4) , but compared with the general population (0.017%) (5) , there is an approximately 10-fold increased risk of development of this solid malignancy. The etiology of this increased risk of RCC is unknown but may be linked to the chronic immunosuppressive state of transplanted patients (2) . Although growing literature shows that RCC is more prevalent in kidneys of patients with ESRD and the native kidneys of transplanted patients, there is a paucity of data on the epidemiology and management of solid renal masses (SRMs) in renal transplant allografts (6) . In this review, we present a summary of the available literature on the incidence of and management patterns for SRMs in allograft kidneys.
Materials and Methods
A literature review using keyword searches in PubMed was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology (7) . Keywords used to identify relevant studies included renal mass, renal cell carcinoma, renal cancer, renal transplant, renal allograft, and kidney or renal transplantation. An abstract review was then performed to identify pertinent studies. Article references were used to further identify all relevant published articles. Studies were defined as pertinent for inclusion if they explored the topic of SRMs in transplant allograft kidneys. All identified, pertinent studies were included in this analysis, including retrospective multi-institutional case series, single-institution case series, and case reports. An individual review of each article was performed, with patient and tumor characteristics extracted for cumulative analysis. If available, the following data points were collected: number of kidney transplants performed at the institution, number of patients with SRMs in allograft kidney, number of SRMs identified, deceased or living donor transplant, size of SRM, how mass was diagnosed, immunosuppressive regimen prior to diagnosis, modifications in immunosuppressive regimen following diagnosis, histologic diagnosis, American Joint Committee on Cancer (AJCC) 2010 staging classification, Fuhrman grade, type of intervention performed, allograft function after treatment, cancer-specific survival, and length of follow-up. Descriptive statistics including frequencies, means, and ranges were calculated from the pooled data. Mean values are reported rather than medians because individual values were not reported by every study reviewed, and thus median values could not be calculated. Cumulative incidence was calculated using the studies that reported the total number of renal transplants performed over the same period in which SRMs were diagnosed in the allograft kidney.
Results
From 1988 to 2016, a total of 56 studies were found reporting on SRMs in transplanted allograft kidneys (3, 4, . Our literature search yielded one multicenter retrospective case series, 19 single-institution case series, and 36 case reports. Fourteen studies reported on the total number of renal transplants performed over the same study period in which the SRMs were diagnosed, allowing for an overall calculated cumulative incidence of RCC in allografts from these studies of 0.23% (152 of 65 667). A total of 174 SRMs in allograft kidneys were identified in 163 patients. All but four patients had clinically localized disease at diagnosis, and all patients with metastases underwent transplant nephrectomies. The mean tumor size of these 174 masses was 2.75 cm (range 0.5-9.0 cm). Information regarding radiographic tumor detection was available in 133 of 163 patients (81.6%). Of these, 105 of 133 patients (79%) were initially diagnosed on routine screening ultrasound, 24 of 133 (18%) were symptomatic, and three of 133 (2.3%) were discovered incidentally on transplant nephrectomy. Symptoms that prompted imaging included hematuria (seven of 24, 29%), acute kidney injury (six of 24, 25%), pain (five of 24, 21%), constitutional symptoms (four of 24, 17%), hypertension (one of 24, 4%), and recurrent urinary tract infections (one of 24, 4%; Table 1 ). Preintervention immunosuppressive regimens were reported in 133 of 163 patients (81.6%), with only one patient reported to have received induction immunosuppression with thymoglobulin. Moreover, 123 of 133 (92.5%) included a calcineurin inhibitor (CNI), whereas the remaining 10 patients were on an antimetabolite and corticosteroid immunosuppressive regimen. The origin of the transplanted allograft in which the SRM occurred (deceased or living donor) was available for 62 of 163 patients (38%). Of these, 46 of 62 patients (74.2%) received an allograft from a deceased donor and 16 of 62 (25.8%) received an allograft from a living donor. Tumor histology was available for 164 of 174 tumors (94.3%) and included clear cell (45.7%), papillary (42.1%), chromophobe (3%), and other variant histologies (oncocytomas, mixed histologies, angiomyolipomas, benign fibrous tumors, and spindle cell carcinoma; 9.1%). A Fuhrman grade designation was available for 127 of 174 tumors (73%): grade I (18.9%), grade II (63.7%), grade III (15.7%), and grade IV (1.6%). Donor origin of the malignant cells was documented through DNA assay in 15 of 163 patients (9.2%). The AJCC 2010 staging classification was available for 154 of 163 patients (94.5%). The majority of patients were pT1a (87%), whereas 9%, 1.3%, and 2.6% were pT1b, pT2a, and pT3a, respectively. In our review of the literature, we did not identify any reports of pT2b, pT3b, pT3c, or pT4 tumors ( Table 2 ).
The treatment modality for management of SRM was reported for all 163 patients. Partial nephrectomy was performed in 110 patients (67.5%), transplant nephrectomy was performed in 32 (19.4%), radiofrequency ablation (RFA) was performed in 17 (10.4%), and cryoablation was performed in four (2.4%) ( Table 2) . Of the 131 patients who underwent nephron-sparing interventions, 7.6% returned to hemodialysis and 6.1% developed tumor recurrence in the allograft over a mean follow-up of 2.85 years. Immunosuppression was altered in 29 patients after nephron-sparing interventions, of which 20 of these changes were to include a mammalian target of rapamycin (mTOR) inhibitor. Of the 110 patients who underwent partial nephrectomy, 3.6% developed local recurrence during a mean follow-up of 3.12 years, and all of these patients ultimately underwent completion transplant nephrectomy. Over a mean follow-up of 1.83 years, three of 17 patients (17.6%) had persistent mass enhancement after RFA, with all residual tumors treated with repeat RFA without evidence of recurrence on follow-up. One patient had decreased renal function prior to RFA that worsened following the procedure and required a return to dialysis. Notably, one patient underwent RFA of two biopsy-proven synchronous clear cell renal carcinomas within a transplanted allograft kidney with no evidence of disease progression at 33-mo follow-up (16) . In the four patients treated with cryotherapy, none experienced local recurrence or return to dialysis during the short mean follow-up of 4.25 mo. Of the 32 patients who underwent primary transplant nephrectomy, 28 had clinically localized disease at time of surgical intervention, with no reports of disease recurrence or metastases following nephrectomy during the available follow-up. Of nine reported deaths, two were renal cancer-specific (8, 42) .
Discussion
This report is the largest cumulative review of available literature exploring the tumor characteristics and management of SRMs in transplant allograft kidneys. As reported in 2013 by the Scientific Registry of Transplant Recipients, 10-year overall graft survival for living and deceased donors increased from 35-40% to 55-60% compared with the previous decade (62). Although our literature review identified a total of only 163 affected patients, we suspect that this increase in overall survival will likely lead to an increased incidence of renal masses in the allograft kidney. Consequently, an increasing number of transplant surgeons and urologists will be faced with this difficult clinical scenario that requires maximizing preservation of renal function while ensuring adequate cancer control.
Immunosuppression has been identified as a risk factor for developing both infectious-mediated malignancies and those without underlying infectious etiology. It is hypothesized that this may be secondary to the immune system having a decreased ability to identify and destroy cancer cells. Although minimal literature links immunosuppression to the development of RCC in the transplanted allograft, a wide body of literature supports the role of immunosuppression in the development of other malignancies, particularly related to oncogenic viruses and nonmelanoma skin cancer (63) . The role of CNIs in the development of malignancy has been explored, with increased levels of VEGF and TGF-b1 identified with CNI use (64) . This upregulation may result in proliferation of malignant cells in patients on CNIs, which the majority of our reviewed patients used prior to diagnosis of SRM. A dose-dependent increase in circulating TGF-b1 has been identified in both in vitro and in vivo analyses (65) . Although the use of low-dose CNI regimens has been associated with a decreased risk of malignancy, an increased risk of acute rejection was seen with lower dose suppression (66) . Less literature supports an increased malignant potential with other immunosuppressive agents such antimetabolites, corticosteroids, and induction therapies; however, this is an area of continuing active research. The utilization of mTOR inhibitors for immunosuppression after transplantation has been shown to lower the rates of de novo malignancy; however, this approach is associated with significant adverse affects leading to discontinuation (67) . After diagnosis of malignancy after transplantation, alterations to the immunosuppressive regimen could include altering the medications used, lowering the dosage, or discontinuing immunosuppression altogether. A reasonable approach may be to change the immunosuppression regimen to an mTOR inhibitor, as seen in 20 of 29 (69%) of the reviewed patients who had changes in their maintenance immunosuppression reported.
The reported incidence of papillary RCC in the transplanted allograft is significantly higher (42.1%) than in the healthy population (10-15%) (68) . In addition, a corresponding decreased incidence of clear cell RCC in allograft kidneys (45.7%) compared with the nontransplant population (75-80%) was noted (68) . Papillary RCC tended to have a multicentric growth pattern in up to 40% of patients and has been noted to occur bilaterally (68) . Although a higher incidence of papillary RCC in native kidneys of ESRD patients is well known (69), it is not clear why this histology appears to demonstrate a predilection for allograft kidneys, independent of posttransplant renal function. Moreover, according to our review, 25.8% of allograft tumors were identified in grafts from living donors, meaning the living donors may be at increased risk of developing papillary RCC in their solitary kidney due to its tendency for multicentricity. Early identification of these masses through screening of affected donors with ultrasound or cross-sectional imaging could allow for nephron-sparing interventions to be performed while the tumor size is small.
Papillary RCC can be associated with activation of the c-MET oncogene, trisomy of chromosome 7 or 17, and loss of chromosome Y; however, this level of data was unavailable for examination in the reviewed literature (68) . To our knowledge, no literature has supported an increased risk of papillary RCC in immunocompromised patients. Meaningful cumulative analysis of immunosuppressive regimens was not feasible in our study because of the limited availability of this information and a general lack of standardized treatment protocol for immunosuppressive agents in the kidney transplant population. In addition, the immunosuppressive agents used after renal transplantation may have direct carcinogenic or nephrotoxic effects on the proximal tubules from which papillary RCC arises. A final possible explanation for the increased prevalence of papillary RCC in this population is that the warm ischemia time associated with renal transplantation may mirror the ischemic state of chronic renal failure that is associated with an increased risk of papillary RCC. Regardless of the potential etiology, identification of the candidate systemic factors that predispose patients to developing metachronous papillary RCC in allograft kidneys may require data granularity at the molecular and genetic levels.
Nephron-sparing interventions are crucial to preserve allograft function should patients develop another tumor in the future. In our review, local recurrence rates following partial nephrectomies in transplant allograft kidneys (3.6%) are comparable to those of partial nephrectomies performed on native kidneys (3%) (70) . This suggests that despite complex surgical anatomy and postoperative adhesions associated with prior kidney transplantation, similar cancer control can be achieved utilizing partial nephrectomy in allograft kidneys. This finding agrees with a prior review that analyzed 59 patients who underwent nephron-sparing interventions with good oncologic outcomes and graft survival (71) . Although the majority of publications utilize an open approach to partial nephrectomy in this patient population, Kaouk et al demonstrated the ability to navigate the unique surgical complexity utilizing a robotic approach (14) . Focal ablative therapies such as RFA or cryoablation offer alternative nephron-sparing options for minimally invasive intervention. Whereas meta-analysis has shown an increased local recurrence rate after RFA or cryoablation compared with partial nephrectomy (72) , more recent data demonstrated no significant difference in local recurrence rates in a 1424-patient cohort (73) . Despite the limitation of a small sample size, there was a high rate of persistent viable tumor after initial RFA that required repeated treatment in this review. Focal ablative therapies could be particularly useful in patients with multiple SRMs in the transplant allograft kidney, as demonstrated by Su et al (16) . In our review of the literature, there was minimal discussion of surveillance protocols after intervention; however, surveillance guidelines similar to those published by the American Urological Association could be adopted in this population (74) .
Although outcomes following surgical extirpation in allograft kidneys closely mirror those of native kidneys, the role of active surveillance remains unclear. In wellselected patients with kidney cancer in the general population, rates of metastatic disease remain low at 1.7% (75) ; it follows that with routine serial imaging and documentation of growth kinetics, a similar protocol of initial observation could be established. The increased prevalence of papillary tumors among patients with allografts suggests that renal mass biopsy-often routinely performed in the setting of ruling out graft failure-can be of use when incorporated into an allograft surveillance program, prior to undertaking a more invasive, definitive intervention that risks sacrificing a transplanted kidney and returning the patient to dialysis. Notably, because of the review nature of our data, we were unable to provide prevalence rates of papillary type I versus type II RCC. This study provides the first cumulative analysis exploring the incidence and management of SRMs in transplanted kidneys. The pooled analyses provide a reference to help guide future treatment of these complex patients.
Identifying an increased incidence of papillary RCC also has important implications in considering active surveillance or ablative therapies for these patients. Our review has limitations, including the heterogeneity of data quality in individual studies and the cumulative pooled nature of the data; therefore, data points of interest were not available for all patients. The studies from which these data are pooled are all retrospective, and most are either single-institution case series or case reports with only short or intermediate-length follow-up. The role of immunosuppressive regimens could not be explored because the majority of the studies did not include detailed discussion of induction and maintenance immunosuppression. Future research could explore the incidence of papillary RCC in other immunocompromised populations and the biochemical pathways that may explain its increased incidence in transplanted kidneys. Further investigation should include looking at the role of specific immunosuppressive protocols on the development of SRMs in transplanted kidneys.
Current management of SRMs in transplant allograft kidneys mirrors management of renal masses in the overall population. As life expectancy improves for renal transplant patients, SRMs will likely become more prevalent. Increased incidence of papillary RCC was noted in the transplant population compared with the nontransplant population and may further increase the utility of renal mass biopsy and renal-preserving strategies in these patients. Even with complex surgical anatomy after renal transplantation, local recurrence rates after partial nephrectomy are comparable to rates seen in native kidneys. Proper surveillance and management of this subpopulation is imperative, as acceptable oncologic outcomes for allograft tumors are achievable.
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